By Donna Loyle, communications specialist, LIMR
Main Line Health is participating in a new phase II clinical trial that seeks to determine how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV, ALK-positive, non-squamous, non-small cell lung cancer. Eligible participants are those who’ve already been treated with a second-generation ALK inhibitor, but their disease has progressed.
The study is comparing several ALK inhibitors, including lorlatinib, ceritinib, alectinib, brigatinib, ensartinib and crizotinib. It also is comparing pemetrexed plus cisplatin and/or carboplatin to determine if chemotherapy may work equal, better or worse in these patients.
Tumors are biopsied for genetic mutations, and participants are placed into appropriate study arms.
Study #NRG-LU003 is approved for all MLH acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email email@example.com or visit https://www.mainlinehealth.org/research/clinical-trials/nrg-lu003